-
摘要: 腹膜是结直肠癌转移的第三常见部位。结直肠癌腹膜转移通常被认为是终末期疾病，预后差。随着系统性药物治疗的进展，转移性结直肠癌患者预后明显改善，但腹膜转移患者生存获益仍然较少。腹膜肿瘤细胞减灭术和腹腔热灌注化疗能够显著改善腹膜转移患者的预后。新型治疗方法如腹腔加压气溶胶化疗、腹腔MOC31PE抗毒素治疗等也随之出现。本文将对结直肠癌腹膜转移治疗的临床研究进行综述。Abstract: Peritoneum is the third common metastatic site of colorectal cancer (CRC) following liver and lung. CRC peritoneal metastasis (PM) has been reckoned as an advanced disease with dismal prognosis. With the development of modern chemotherapeutic modalities, the prognosis of patients with metastatic CRC has been dramatically improved, yet patients with CRC PM achieved few survival benefits. It is the emergence and combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy that prolong the survival of PM cases. What's more, novel treatments, pressurized intraperitoneal aerosol chemotherapy, and intraperitoneal MOC31PE immunotoxin treatment, for instance, have been under investigation and preliminary results are promising. We aim to comprehensively review the literature focusing on the clinical treatment of PM.
-
表 1 PSDSS评分标准
表 2 BIOSCOPE评分标准
-
[1] Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases:A randomised trial[J]. Eur J Cancer, 2016, 53:155-162. doi: 10.1016/j.ejca.2015.09.017 [2] Choudry HA, Bednar F, Shuai Y, et al. Repeat Cytoreductive SurgeryHyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases[J]. Ann Surg Oncol, 2019, 26(5):1445-1453. doi: 10.1245/s10434-019-07218-w [3] Alyami M, Hubner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy:rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7):e368-e377. doi: 10.1016/S1470-2045(19)30318-3 [4] Koumpa FS, Xylas D, Konopka M, et al. Colorectal Peritoneal Metastases:A Systematic Review of Current and Emerging Trends in Clinical and Translational Research[J]. Gastroenterol Res Prac, 2019, 5180895. http://cn.bing.com/academic/profile?id=276995a79b0c1b9ca30f206d98aa6729&encoded=0&v=paper_preview&mkt=zh-cn [5] Goere D, Sourrouille I, Gelli M, et al. Peritoneal Metastases from Colorectal Cancer:Treatment Principles and Perspectives[J]. Surg Oncol Clin N Am, 2018, 27(3):563-583. http://cn.bing.com/academic/profile?id=678180fed7362291b313c76a1499b9a0&encoded=0&v=paper_preview&mkt=zh-cn [6] Zhang H, Dai WX, Fu CX, et al. Diagnostic value of whole-body MRI with diffusion-weighted sequence for detection of peritoneal metastases in colorectal malignancy[J]. Cancer Biol Med, 2018, 15(2):165-170. doi: 10.20892/j.issn.2095-3941.2017.0162 [7] Vassos N, Piso P. Metastatic Colorectal Cancer to the Peritoneum:Current Treatment Options[J]. Curr Treat Options Oncol, 2018, 19(10):49. doi: 10.1007/s11864-018-0563-8 [8] Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1, 013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis[J]. Ann Surg Oncol, 2014, 21(13):4195-4201. http://cn.bing.com/academic/profile?id=71708983011da82fe82799d260808f35&encoded=0&v=paper_preview&mkt=zh-cn [9] Arjona-Sanchez A, Rodriguez-Ortiz L, Baeatti D, et al. RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis:A Modification Proposal of the Peritoneal Surface Disease Severity Score[J]. Ann Surg Oncol, 2019, 26(8):2595-2604. doi: 10.1245/s10434-019-07378-9 [10] Schneider MA, Eden J, Pache B, et al. Mutations of RAS/RAF Protooncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin[J]. Ann Surg, 2018, 268(5):845-853. https://www.ncbi.nlm.nih.gov/pubmed/30303876 [11] Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States[J]. Ann Surg Oncol, 2014, 21(5):1501-1505. doi: 10.1245/s10434-013-3061-z [12] Mogal H, Chouliaras K, Levine, EA et al. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy:review of indications and outcomes[J]. J Gastrointest Oncol, 2016, 7(1):129-142. http://cn.bing.com/academic/profile?id=cf624dc89706699a3cdc80a4672cff43&encoded=0&v=paper_preview&mkt=zh-cn [13] Huang YQ, Alzahrani NA, Chua TC, et al. Repeat cytoreductive surgery with or without perioperative intraperitoneal chemotherapy for peritoneal surface malignancy[J]. Am J Surg, 2017, 213(6):1024-1030. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_a9e4b21f22d2408e70bd64750d0c5ddf [14] Jacobson R, Sherman SK, Dadaleh F, et al. Peritoneal Metastases in Colorectal Cancer[J]. Ann Surg Oncol, 2018, 25(8):2145-2151. doi: 10.1245/s10434-018-6490-x [15] Hall B, Padussis J, Foster JM. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis[J]. Surg Clin North Am, 2017, 97(3):671-682. doi: 10.1016/j.suc.2017.01.013 [16] Quenet F, Elias D, Roca L, et al. A UNICANCER phase Ⅲ trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC):PRODIGE 7[J]. Journal of Clinical Oncology, 2018, 36(18_suppl):LBA3503-LBA. doi: 10.1200/JCO.2018.36.18_suppl.LBA3503 [17] Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer:a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS[J]. Ann Oncol, 2018, 29(1):44-70. doi: 10.1093/annonc/mdx738 [18] 赵志勋, 裴炜, 熊斌, 等.结直肠癌腹膜转移诊治中国专家意见(2017)[J].中华结直肠疾病电子杂志, 2017, 6(5):360-366. doi: 10.3877/cma.j.issn.2095-3224.2017.05.002 [19] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer Version 2.2019[R/OL].https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. [20] Siebert M, Alyami M, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study[J]. Eur J Surg Oncol, 2019, Mar 20[Online ahead of print] [21] Farinha HT, Grass F, Labgaa I, et al. Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy[J]. J Cancer, 2018, 9(1):13-20. doi: 10.7150/jca.21460 [22] Larbre V, Alyami M, Mercier F, et al. No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis[J]. Anticancer Res, 2018, 38(12):6869-6875. doi: 10.21873/anticanres.13062 [23] Graversen M, Detlefsen S, Bjerregaard JK, et al. Prospective, singlecenter implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis[J]. Ther Adv Med Oncol, 2018, 10, 1758835918777036. doi: 10.1177/1758835918777036 [24] Girshally R, Demtroder C, Albayrak N, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. World J Surg Oncol, 2016, 14(1):253. doi: 10.1186/s12957-016-1008-0 [25] Frøysnes IS, Andersson Y, Larsen SG, et al. Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis:Results From the ImmunoPeCa Phase 1 Trial[J]. Ann Surg Oncol, 2017, 24(7):1916-1922. doi: 10.1245/s10434-017-5814-6 [26] Føysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis[J]. Eur J Surg Oncol, 2019, Apr 22[Online ahead of print] [27] Elias D, Faron M, Iuga BS, et al. Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers[J]. Ann Surg, 2015, 261(1):157-163. doi: 10.1097/SLA.0000000000000582 [28] Ceelen W, Nieuwenhove YV, Putte DV, et al. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis[J]. Ann Surg Oncol, 2014, 21(9):3023-3028. doi: 10.1245/s10434-014-3713-7 [29] Waite K, Youssef H. The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases:A Systematic Review[J]. Ann Surg Oncol, 2017, 24(3):705-720. http://cn.bing.com/academic/profile?id=1f8f144e78688953c4c51c23fd15430d&encoded=0&v=paper_preview&mkt=zh-cn -
点击查看大图
表(2)
计量
- 文章访问数: 369
- HTML全文浏览量: 38
- PDF下载量: 48
- 被引次数: 0
下载:
